AML-NET : Acute Myeloid Leukemia treated with with NETrin Abs in combination with [AZACITIDINE + VENETOCLAX]

2023-503408-10-00 Protocol ET23-026 Phase I and Phase II (Integrated) - Other Ended

Start 8 Sep 2024 · End 4 Jul 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol ET23-026

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 35
Countries 1
Sites 2

Refractory Acute Myeloïd Leukemia

Key facts

Sponsor
Centre Leon Berard
Participant type
Patients
Age range
65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
8 Sep 2024 → 4 Jul 2025
Decision date (initial)
2023-08-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Refractory Acute Myeloïd Leukemia

VersionLevelCodeTermSystem organ class
21.0 LLT 10000886 Acute myeloid leukemia 10029104
21.1 LLT 10081514 Acute myeloid leukemia refractory 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Leon Berard

Sponsor organisation
Centre Leon Berard
Address
28 Rue Laennec
City
Lyon
Postcode
69008
Country
France

Scientific contact point

Organisation
Centre Leon Berard
Contact name
Oncology Doctor

Public contact point

Organisation
Centre Leon Berard
Contact name
Clinical Project Manager

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 35 2
Rest of world 0

Investigational sites

France

2 sites · Ended
Centre Leon Berard
Medical oncology, 28 Rue Laennec, 69008, Lyon
Hospices Civils De Lyon
Medical oncology, 165 Chemin Du Grand Revoyet, 69310, Pierre-Benite

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-09-08 2024-09-08 2025-02-18

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-17 France Acceptable
2023-08-25
2023-08-25
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-09-26 France Acceptable
2023-08-25
2023-09-26
3 SUBSTANTIAL MODIFICATION SM-1 2023-09-27 France Acceptable 2023-11-17
4 SUBSTANTIAL MODIFICATION SM-2 2024-03-22 France Acceptable
2024-05-06
2024-05-29
5 NON SUBSTANTIAL MODIFICATION NSM-2 2025-07-04 France Acceptable
2024-05-06
2025-07-04